SCHEMBL505679

SCHEMBL505679

N#CCNCCNCC#N

nearest known ligand 0.38

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA4 P22748 1/20 0.38
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12921486 0.96 CA12 (0.36) ALDH1A1CA12CA1CA2CA4
SCHEMBL14942749 0.85 CA12 (0.32) CA12CA1CA2CA4
SCHEMBL428246 0.84
SCHEMBL11495876 0.84 ALDH1A1 (0.43) ALDH1A1CA12CA1CA2CA4
SCHEMBL10656674 0.83
SCHEMBL5984178 0.83
SCHEMBL12391588 0.83 TSHR (0.38) ALDH1A1CA12CA1CA2CA4
SCHEMBL1264138 0.83 CA12 (0.58) ALDH1A1CA12CA1CA2CA4
SCHEMBL1980415 0.81
SCHEMBL1219884 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778618-B1 SYNTHESIS OF TRIETHYLENETETRAMINES PHILERA NEW ZEALAND LTD (NZ) 2013-12-25 EP claimed
US-7582796-B2 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PROTEMIX CORPORATION LIMITED (NZ) 2009-09-01 US claimed
EP-1778618-A4 SYNTHESIS OF TRIETHYLENETETRAMINES PROTEMIX CORP LTD (NZ) 2008-07-16 EP claimed
EP-1778618-A2 SYNTHESIS OF TRIETHYLENETETRAMINES Protemix Corporation Limited (NZ) 2007-05-02 EP claimed
WO-2006027705-A2 SYNTHESIS OF TRIETHYLENETETRAMINES PROTEMIX CORPORATION LIMITED (NZ) 2006-03-16 WO claimed
US-20060041170-A1 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PHILERA NEW ZEALAND LIMITED (NZ) 2006-02-23 US claimed
WO-2024018394-A1 A PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM A OF N, N'-BIS(2-AMINOETHYL)-1,2-ETHANEDIAMINE TETRAHYDROCHLORIDE BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) 2024-01-25 WO disclosed
US-11795150-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2023-10-24 US disclosed
US-11795150-B2 Synthesis of triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2023-10-24 US disclosed
EP-3350154-B1 AN IMPROVED PROCESS FOR PREPARATION OF TRIENTINE DIHYDROCHLORIDE EMCURE PHARMACEUTICALS LTD (IN) 2021-02-17 EP disclosed
EP-3350154-B1 AN IMPROVED PROCESS FOR PREPARATION OF TRIENTINE DIHYDROCHLORIDE EMCURE PHARMACEUTICALS LTD (IN) 2021-02-17 EP disclosed
US-20200148647-A1 Synthesis of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2020-05-14 US disclosed
US-20200148647-A1 Synthesis of Triethylenetetramines PHILERA NEW ZEALAND LIMITED (NZ) 2020-05-14 US disclosed
WO-2008104552-A1 PRODUCTION METHOD FOR ETHYLENEAMINE MIXTURES BASF SE (DE) 2008-09-04 WO disclosed
EP-1778618-A4 SYNTHESIS OF TRIETHYLENETETRAMINES PROTEMIX CORP LTD (NZ) 2008-07-16 EP disclosed
EP-1778618-A2 SYNTHESIS OF TRIETHYLENETETRAMINES Protemix Corporation Limited (NZ) 2007-05-02 EP disclosed
WO-2006027705-A2 SYNTHESIS OF TRIETHYLENETETRAMINES PROTEMIX CORPORATION LIMITED (NZ) 2006-03-16 WO disclosed
US-20060041170-A1 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride PHILERA NEW ZEALAND LIMITED (NZ) 2006-02-23 US disclosed
EP-0934278-B1 BIS(ACRIDINECARBOXAMIDE) AND BIS(PHENAZINECARBOXAMIDE) AS ANTITUMOUR AGENTS XENOVA LTD (GB) 2002-09-04 EP disclosed
US-6114332-A BACTERICIDES XENOVA LIMITED (GB) 2000-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795150-B2 Synthesis of triethylenetetramines PNMT, TES, TPR ALDH1A1 4075/4885CA12 3847/4885CA1 3131/4885
US-20200148647-A1 Synthesis of Triethylenetetramines PNMT, TES, TPR ALDH1A1 4075/4885CA12 3847/4885CA1 3131/4885
US-20060041170-A1 starting the reaction of alkylating ethylenediamine with formaldehyde to form pure triethylenetetramine; salt formation of triethylenetetramine disuccinate or triethylenetetramine tetrahydrochloride TET1, TET2, TET3 ALDH1A1 3779/4885CA12 1751/4885CA1 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.